Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
| Autor: | Martin A. Kennedy, Oluseye O. Bolaji, Olalekan Olasehinde, Ayorinde Adehin, Olusegun I. Alatise, Julius O. Soyinka |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study Tumor biology business.industry Population Estrogen receptor Context (language use) medicine.disease Breast cancer Internal medicine medicine Adjuvant therapy Tamoxifen therapy skin and connective tissue diseases business education Tamoxifen medicine.drug |
| Zdroj: | Breast Cancer: Targets and Therapy. 12:123-130 |
| ISSN: | 1179-1314 |
| DOI: | 10.2147/bctt.s266314 |
| Popis: | Estrogen-receptor positivity in tumour, often requiring long-term tamoxifen therapy, is thought to characterise between 43% and 65% of breast cancer cases in Nigeria. The patient population is further marked by late-stage diagnosis which significantly heightens the tendency for tumour relapse in the course of tamoxifen therapy. Despite tamoxifen being considered a reliable chemopreventive in high-risk individuals and an effective adjuvant therapy for hormone-sensitive tumours, mortality has remained high among breast cancer patients in the West African region where Nigeria belongs. The Nigerian breast cancer population, like other similar patient-populations in the West African region, provides a mix of intrinsic genome-diversity and perhaps unique tumour biology and evolution. These peculiarities suggest the need for a rational approach to tumour management and a personalised delivery of therapy in Nigeria's dominant estrogen-receptor-positive patient population. Herein, critical indices of tamoxifen-therapy success are discussed in the context of the Nigerian breast cancer population with emphasis on salient aspects of tamoxifen-biotransformation, host- and tumour-genomics, and epigenetics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|